False
November 3, 2026
2 min read
The company also reported early efficacy and safety data from the Phase I Breakfree-2 study
November 2, 2026
2 min read
Phase I data show B-cell depletion and mostly stable or improved disability scores, but the uncontrolled study remains small and follow-up is limited
October 27, 2026
2 min read
Global deployment of Veeva Vault CRM aims to help Amgen uncover treatment barriers and accelerate the delivery of new therapies
October 22, 2026
5 min read
Rob DiCicco discusses how FDA–industry collaboration is helping sponsors rethink safety reporting, selective safety data collection, and pragmatic clinical trial design.
False